Juillerat Alexandre, Marechal Alan, Filhol Jean-Marie, Valton Julien, Duclert Aymeric, Poirot Laurent, Duchateau Philippe
Cellectis Inc, 430E, 29th street, NYC, NY 10016, USA.
Cellectis SA, 8 rue de la croix Jarry, 75013 Paris.
Sci Rep. 2016 Jan 11;6:18950. doi: 10.1038/srep18950.
The ability to control T cells engineered to permanently express chimeric antigen receptors (CARs) is a key feature to improve safety. Here, we describe the development of a new CAR architecture with an integrated switch-on system that permits to control the CAR T-cell function. This system offers the advantage of a transient CAR T-cell for safety while letting open the possibility of multiple cytotoxicity cycles using a small molecule drug.
控制经基因工程改造以永久表达嵌合抗原受体(CAR)的T细胞的能力是提高安全性的关键特性。在此,我们描述了一种具有集成开启系统的新型CAR架构的开发,该系统可控制CAR T细胞的功能。该系统具有提供瞬时CAR T细胞以提高安全性的优势,同时保留了使用小分子药物进行多个细胞毒性循环的可能性。